FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

NATCO Pharma Lansoprazole Delayed-Release Capsules Recall

Lansoprazole Delayed-Release Capsules USP, 15 mg, 14-count bottle, Manufactured by: Nat…

NATCO Pharma Limited

Risk level
Class II
Reported by FDA
Feb 14, 2024
Recall ID
D-0318-2024
Check your lot numberHow we source this data

Summary

NATCO Pharma recalled Lansoprazole Delayed-Release Capsules starting Feb 1, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0318-2024 on Feb 14, 2024. Reason: CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules with holes and spheres sticking to capsules. Also coding details were missing on one bottle. Status: Terminated.

Why it was recalled

CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules with holes and spheres sticking to capsules. Also coding details were missing on one bottle.

Product description

Lansoprazole Delayed-Release Capsules USP, 15 mg, 14-count bottle, Manufactured by: Natco Pharma Limited Kothur- 509 228, India, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ. 08816. NDC 16571-742-41

Lot numbers, UPCs & expiration codes

Lot # 411987 Exp: 05/2025

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0318-2024
Classification
Class II
Status
Terminated
Recall initiated
Feb 1, 2024
FDA report date
Feb 14, 2024
Quantity
4260 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
NATCO Pharma Limited

Original FDA data

Every field from FDA enforcement report D-0318-2024, exactly as published.

Show all FDA fields
City
Rangareddy
Status
Terminated
Country
India
Event ID
93868
Address
Pharma Division, Kothur Village
Code information
Lot # 411987 Exp: 05/2025
Report date
Feb 14, 2024
Product type
Drugs
Recall number
D-0318-2024
Classification
Class II
Recalling firm
NATCO Pharma Limited
Product quantity
4260 bottles
Termination date
Feb 6, 2026
Reason for recall
CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules with holes and spheres sticking to capsules. Also coding details were missing on one bottle.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lansoprazole Delayed-Release Capsules USP, 15 mg, 14-count bottle, Manufactured by: Natco Pharma Limited Kothur- 509 228, India, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ. 08816. NDC 16571-742-41
Distribution pattern
Nationwide in the USA
Recall initiation date
Feb 1, 2024
Initial firm notification
Letter
Center classification date
Feb 8, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0318-2024, published Feb 14, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls